1. Home
  2. RGLS vs FNGR Comparison

RGLS vs FNGR Comparison

Compare RGLS & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • FNGR
  • Stock Information
  • Founded
  • RGLS 2007
  • FNGR 2016
  • Country
  • RGLS United States
  • FNGR Singapore
  • Employees
  • RGLS N/A
  • FNGR N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • FNGR Computer Software: Prepackaged Software
  • Sector
  • RGLS Health Care
  • FNGR Technology
  • Exchange
  • RGLS Nasdaq
  • FNGR Nasdaq
  • Market Cap
  • RGLS 106.7M
  • FNGR 108.1M
  • IPO Year
  • RGLS 2012
  • FNGR N/A
  • Fundamental
  • Price
  • RGLS $1.48
  • FNGR $1.92
  • Analyst Decision
  • RGLS Strong Buy
  • FNGR
  • Analyst Count
  • RGLS 6
  • FNGR 0
  • Target Price
  • RGLS $10.33
  • FNGR N/A
  • AVG Volume (30 Days)
  • RGLS 263.0K
  • FNGR 176.1K
  • Earning Date
  • RGLS 11-07-2024
  • FNGR 10-15-2024
  • Dividend Yield
  • RGLS N/A
  • FNGR N/A
  • EPS Growth
  • RGLS N/A
  • FNGR N/A
  • EPS
  • RGLS N/A
  • FNGR N/A
  • Revenue
  • RGLS N/A
  • FNGR $31,176,174.00
  • Revenue This Year
  • RGLS N/A
  • FNGR $260.03
  • Revenue Next Year
  • RGLS N/A
  • FNGR N/A
  • P/E Ratio
  • RGLS N/A
  • FNGR N/A
  • Revenue Growth
  • RGLS N/A
  • FNGR N/A
  • 52 Week Low
  • RGLS $1.08
  • FNGR $1.63
  • 52 Week High
  • RGLS $3.79
  • FNGR $6.15
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 44.54
  • FNGR 40.38
  • Support Level
  • RGLS $1.47
  • FNGR $2.06
  • Resistance Level
  • RGLS $1.65
  • FNGR $2.46
  • Average True Range (ATR)
  • RGLS 0.11
  • FNGR 0.14
  • MACD
  • RGLS -0.00
  • FNGR -0.03
  • Stochastic Oscillator
  • RGLS 15.79
  • FNGR 16.92

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

Share on Social Networks: